Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD3, CD4, and CD8 are critical surface antigens present on different subsets of human T lymphocytes. CD3 antigen is a multisubunit protein complex associated with the T cell receptor (TCR), serving as a key signal transduction adaptor. It is used as a pan-T cell marker and is essential for T cell activation. CD4 antigen acts as a co-receptor on helper T cells, binding to MHC class II molecules and facilitating immune coordination and activation; it is a primary target for HIV entry. CD8 antigen serves as a co-receptor on cytotoxic T cells, binding MHC class I molecules and enabling recognition/killing of infected and cancerous cells. All three are leveraged as diagnostic markers and therapeutic targets in immuno-oncology, infectious diseases, and immune modulation, but should be treated as separate, distinct targets for structural annotation and drug development.
Targeting these antigens involves modulation or depletion of T cells, induction of signaling, immunosuppression, inhibition of HIV entry, or enhancement of T cell-mediated cytotoxicity to influence immune responses.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD3, CD4, CD8 antigens (CD3, CD4, CD8).